| Ytd | 21.37% | |
| 1y | 56.77% |
| Open | 58.00 | Prev Close | 58.04 | Low | 56.00 | High | 58.59 | Mkt Cap | 8.38B |
| Vol | 811.03K | Avg Vol | 1.61M | EPS | -7.21 | P/E | -8.14 | Forward P/E | -7.84 |
| Beta | 1.22 | Short Ratio | 8.98 | Inst. Own | 113.92% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 52.52 | 200-d Avg | 51.54 | 1yr Est | 109.00 |
PCVX News
SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Prov
The health care sector's most oversold stocks are a buying opportunity due to undervalued compan
Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(2.30) per share which missed the analyst consen
Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prev
Vaxcyte is evolving from a single-product biotech into a commercial vaccine platform with advanced m
SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stag
Vaxcyte's next-generation 31-valent pneumococcal conjugate vaccine (PCV) candidate, for the prev
OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines
Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 a
Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 a
Bridgefront Capital LLC boosted its holdings in shares of Vaxcyte, Inc. (NASDAQ: PCVX) by 127.2% dur
Citigroup Inc. reduced its stake in shares of Vaxcyte, Inc. (NASDAQ: PCVX) by 27.1% in the third qua
BTIG analyst Thomas Shrader maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price targe
Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript
Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.80) per share which missed the analyst consen
Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FD
China Universal Asset Management Co. Ltd. lessened its holdings in shares of Vaxcyte, Inc. (NASDAQ:
Vaxcyte (NASDAQ: PCVX) executives used a presentation at an annual biotech summit to highlight progr
Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced that the f
Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomi
SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage
Federated Hermes Inc. raised its position in Vaxcyte, Inc. (NASDAQ: PCVX) by 6,856.3% in the undefin
SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage
SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage
SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it h
Vaxcyte shares rise after starting Phase 3 trials for its VAX-31 pneumonia vaccine, expanding studie
VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Ad
Needham analyst Joseph Stringer maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price t
